Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the Phase 3 YOSEMITE clinical trial for zodasiran, its RNAi therapeutic targeting ANGPTL3 for treating homozygous familial hypercholesterolemia (HoFH). This rare genetic condition causes severely elevated LDL-cholesterol levels and early cardiovascular disease.
Zodasiran becomes Arrowhead's fourth RNAi candidate to reach late-stage pivotal studies, following plozasiran, fazirsiran (licensed to Takeda), and olpasiran (licensed to Amgen). Phase 2 results showed promising reductions in LDL-C, ApoB, non-HDL-C, and triglycerides in HoFH patients.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. EDT, and at the 46th Annual Goldman Sachs Global Healthcare Conference on June 9 at 2:00 p.m. EDT. Both presentations will be in a fireside chat format. Interested parties can access the presentation webcasts through the Events and Presentations page in the Investors section of Arrowhead's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong fiscal Q2 2025 results, marking significant financial and operational progress. The company posted revenue of $542.7 million, compared to no revenue in Q2 2024, and net income of $370.4 million versus a loss of $125.3 million year-over-year. Following a major licensing deal with Sarepta Therapeutics worth $825 million upfront, Arrowhead is now funded into 2028.
The FDA has accepted the NDA for plozasiran for FCS treatment, with a PDUFA date of November 18, 2025. The company's financial position strengthened with total cash resources reaching $1.1 billion as of March 31, 2025. Additionally, CFO Ken Myszkowski will retire, to be succeeded by Daniel Apel effective May 13, 2025.
[ "Revenue surged to $542.7M in Q2 2025 from zero in Q2 2024", "Net income improved to $370.4M from a loss of $125.3M year-over-year", "Secured $825M upfront from Sarepta deal ($500M cash + $325M equity investment)", "FDA accepted NDA for plozasiran with PDUFA date set", "Cash resources increased to $1.1B, with funding secured through 2028", "Potential for $10B in milestone payments from Sarepta partnership" ]Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in two major investor conferences in May 2025. The company will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 11:20 a.m. PDT, and at the 2025 RBC Capital Markets Global Healthcare conference on May 20, 2025, at 2:35 p.m. EDT. Both presentations will be in a fireside chat format and webcasts will be accessible through the Events and Presentations page in the Investors section of Arrowhead's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has scheduled its fiscal 2025 second quarter financial results webcast and conference call for May 12, 2025, at 4:30 p.m. ET. The presentation will cover financial performance for the quarter ended March 31, 2025.
Investors can access the live audio webcast through the Events and Presentations page in the Investors section of the Arrowhead website. A replay option will be available approximately two hours after the call concludes.
For analysts interested in participating in the conference call, registration is required at the provided media server link. Upon registration, participants will receive a personalized PIN code and dial-in number for call access.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a key leadership transition, with Daniel Apel appointed as the new Chief Financial Officer, effective May 13, 2025. He will succeed Ken Myszkowski, who is retiring after 16 years with the company. Myszkowski will remain as an employee adviser to ensure a smooth transition.
Apel joins Arrowhead from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis (2019-2024). His extensive experience includes nearly 20 years at Bayer, where he held positions as CFO of Bayer U.S. (2016-2019) and CFO of Bayer Canada. The transition comes as Arrowhead prepares for its planned launch of plozasiran this year, pending regulatory approval, marking the company's shift from development to commercial stage.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced the approval of inducement grants for 21 new employees by its Board of Directors on April 3, 2025. The grants, approved under NASDAQ Listing Rule 5635(c)(4), collectively provide up to 34,190 restricted stock units to the new hires. These equity awards are structured outside the company's stockholder-approved equity incentive plans and feature a four-year annual vesting schedule.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced topline results from Part 2 of its Phase 1/2 study of ARO-C3, an RNAi therapeutic targeting complement component 3 (C3) for complement-mediated diseases. The study focused on patients with IgA nephropathy (IgAN).
Key findings from the trial (n=14) include:
- Mean sustained C3 reduction >87% through week 24
- Mean sustained AH50 reduction >76% through week 24
- Mean sustained Wieslab AP reduction >89% through week 24
- Mean reduction in spot UPCR of 41% by week 24, with maximum individual reduction of 89%
The treatment was generally well-tolerated with no serious adverse events reported. The most common side effects were headache, cough, and nasopharyngitis. The duration of effect supports quarterly or less frequent subcutaneous dosing in future studies. Additional results will be presented at a medical meeting in 2025.